Skinbiotherapeutics Share Discussion Threads

[onedayrodders] 02/12/2017 18:38

So we have moved on from getting free shares to the actual ratio


;o)

[bobalot] 02/12/2017 13:21

ODR --- THAT WILL IMPROVE SKINBIO'S LIQUIDITY --- but don't expect free stock on a 1:1 ratio....more like 1:200 or 1:400.

At these prices its better to buy in direct without having to pay tax OR HAVING A LOCK IN PERIOD.

OPTI ARE ACTUALLY DEPLETING THEIR OWN VALUE BY THE WAY.

[elrico] 01/12/2017 20:40

Now, now Rodders...behave yourself. ;)

[onedayrodders] 01/12/2017 20:37

Great news today ... especially for OPTI holders who will soon get free SBTX shares

;o)

[bobalot] 01/12/2017 11:19

They all equate to the largest and more affluent population centres --- they will need a separate registration for India who have a more difficult process for patent awards. Which is still a bone of contention for Western big Pharams.

But everything is looking good so far for SBTX clinical and cosmetic creams imo.

[bobalot] 01/12/2017 10:59

IN TODAYS RNS ALONG WITH THE USA and others....SBTX is planning global distribution through a big brand name imo.

The patent is in active prosecution in other locations worldwide including Europe, USA and China.

[polus] 01/12/2017 10:19

Has China been mentioned anywhere?

[bobalot] 01/12/2017 09:32

Selling the first product in China is most definitely on the cards..post patent registration. That's the largest market in the world and it happens to be upwardly mobile with a middle class population in excess of 500 million.

[rathean] 01/12/2017 09:29

I like bob. He ramps my shares :)

[loungeact] 01/12/2017 09:06

Lol, oh bob..

[bobalot] 01/12/2017 09:05

The human trials will only take a month and after the extensive testing already done on live skin looks to be a formality to confirm results.

[bobalot] 01/12/2017 09:03

Excellent news this morning. As a concurrent exercise SBTX is preparing for a GLOBAL LAUNCH LATER NEXTT YEAR.

The patent is in active prosecution in other locations worldwide including Europe, USA and China.

Dr Catherine O'Neill, CEO of SkinBioTherapeutics, commented:

"The Australian skincare market is a key global market. The progression and successful grant of the first national patent to emerge from the Company's Skinbiotix(R) patent family underpins the commercial potential worldwide.

"This is a step forward in preparing for human trials, which are scheduled for 2018."

[loungeact] 01/12/2017 08:26

SkinBioTherapeutics plc Notification of first patent grant.


SkinBioTherapeutics plc (LON:SBTX), a life science company focused on skin health, announces the granting of the first patent for its SkinBiotix® technology in Australia.
The patent granted covers the use of specific probiotic bacteria and lysates in the treatment of skin in health and disease. This marks the Company’s first patent to progress to grant from within its portfolio of patents pending estate. The patent, numbered 2013246701 and entitled ‘Probiotic bacteria’, runs until 15 March 2033.
The patent is in active prosecution in other locations worldwide including Europe, USA and China.

Dr Catherine O’Neill, CEO of SkinBioTherapeutics plc, commented:

“The Australian skincare market is a key global market. The progression and successful grant of the first national patent to emerge from the Company’s Skinbiotix® patent family underpins the commercial potential worldwide.
“This is a step forward in preparing for human trials, which are scheduled for 2018.”


SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas.

[someuwin] 01/12/2017 07:29

Patent grant

[loungeact] 01/12/2017 00:18

“Mr. Rillorta predicted that recent research demonstrating the benefits of probiotics for skin health would propel the ingredient in the personal care space. He anticipates this “will likely be the next big area of growth for probiotics.”“

[loungeact] 01/12/2017 00:09

Probiotics and eczema.

[bobalot] 30/11/2017 12:50

Nice find Someuwin.

[rafboy] 30/11/2017 10:09

Thanks, it may make some people have a look at SBTX. I think the current share price is a bargain as I am hoping the shares will triple from here in 2018.

[someuwin] 30/11/2017 10:07

...More of a factual piece about the company. No price analysis from Shares themselves.

[rafboy] 30/11/2017 09:59

Is it positive?

[someuwin] 30/11/2017 09:54

Big two page spotlight feature on SkinBioTherapeutics in Today's Shares magazine (online).

[onedayrodders] 29/11/2017 18:20

No fight in silver at all currently :0(

[bobalot] 29/11/2017 15:43

SBTX is I believe involved with the Manchester Science Park initiative...take a look at this website and see the lab facilities that have open access. SBTX have leased a lab until next June. This is about the most interesting collaboration I have seen in Britain for a very long time.